Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Evaluation of Rivaroxaban Versus Warfarin for the Treatment of Cerebral Vein Thrombosis: A Case-Control Blinded Study Publisher



Khorvash F1 ; Farajpourkhanaposhtani MJ2 ; Hemasian H2 ; Saadatnia SM1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Isfahan Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Current Journal of Neurology Published:2021


Abstract

Background: Anticoagulation therapy following cerebral vein thrombosis (CVT) can improve mortality and morbidity. Vitamin K antagonists are currently the routine oral anticoagulant used for CVT; while by introduction of rivaroxaban, a direct factor Xa inhibitor, the attentions have been deviated toward novel agents, but the evidence is not strong. The current study is aimed to compare the efficacy and safety of rivaroxaban versus warfarin for anticoagulation therapy of CVT. Methods: The current randomized clinical trial has been conducted on 50 patients with CVT among which, 25 ones were randomly allocated to rivaroxaban treatment (20 mg per day for three months) and remained 25 ones to warfarin treatment [adjusted based on international normalized ratio (INR) of 2-3]. The Modified Rankin Scale (mRS) and clinical investigations, including the incidence of seizure, papilledema, intra/extra-cranial bleeding, blurred vision, headache, nausea and vomiting, and death were evaluated at discharge time and within 3 and 6 months following CVT incidence; eventually, two groups were compared. Results: Comparison of mRS scores between the groups revealed significant differences in none of the interval assessments, at the time of admission (P = 0.510), within three months (P = 0.630), and within six months (P = 0.990), while both of the approaches led to significant decrease in mRS scores following both of the treatments (P < 0.001). The comparison of drug-related adverse effects showed insignificant difference between warfarin versus rivaroxaban (P > 0.050). Conclusion: Based on this study, rivaroxaban is an efficacious agent for the treatment of CVT without remarkable adverse effects. © 2021 Iranian Neurological Association, and Tehran University of Medical Sciences Published by Tehran University of Medical Sciences.
Related Docs
View other Related Docs
1. Utilization and Prescribing Pattern of Rivaroxaban in a Large Teaching Hospital in Iran, Iranian Journal of Pharmaceutical Sciences (2021)
2. Rivaroxaban in Recurrent Ischemic Stroke Due to Protein S Deficiency: A Case Report, Neurology and Therapy (2021)
3. Predictors of Cerebral Venous Thrombosis and Arterial Ischemic Stroke in Young Asian Women, Journal of Stroke and Cerebrovascular Diseases (2012)
4. Impact of Factor Viii and Von Willebrand Factor Plasma Levels on Cerebral Venous and Sinus Thrombosis: Are They Independent Risk Factors?, European Neurology (2011)
5. Are Cerebral Veins Hounsfield Unit and H: H Ratio Calculating in Unenhanced Ct Eligible to Diagnosis of Acute Cerebral Vein Thrombosis?, Journal of Research in Medical Sciences (2019)
6. Seizure in Cerebral Venous and Sinus Thrombosis, Epilepsia Open (2018)
7. Risk Factors for Remote Seizure Development in Patients With Cerebral Vein and Dural Sinus Thrombosis, Seizure (2014)
8. Factor V Leiden, Factor V Cambridge, Factor Ii Ga20210, and Methylenetetrahydrofolate Reductase in Cerebral Venous and Sinus Thrombosis: A Case-Control Study, Journal of Research in Medical Sciences (2015)
Experts (# of related papers)
View all Related Experts
Mohammad Saadatnia (15)
Masoumeh Sadeghi (6)
Other Related Docs
9. Rivaroxaban Population Pharmacokinetic and Pharmacodynamic Modeling in Iranian Patients, Journal of Clinical Pharmacy and Therapeutics (2022)
10. Anticoagulant Therapy for Ischemic Stroke: A Review of Literature, Journal of Research in Medical Sciences (2012)
11. The Prediction Role of D-Dimer in Recurrence of Venous Thromboembolism 1-Year After Anticoagulation Discontinuing Following Idiopathic Deep Vein Thrombosis, Journal of Research in Medical Sciences (2014)
12. Continuous Infusion Versus Intermittent Intravenous Heparin Injection Effect on Coagulation State After Peripheral Vascular Surgery, Journal of Isfahan Medical School (2011)
13. Soluble Thrombomodulin and Endothelial Cell Protein C Receptor Levels in Patients With Cerebral Venous and Sinus Thrombosis, European Neurology (2013)
14. Sex Differences in Cerebral Venous Sinus Thrombosis After Adenoviral Vaccination Against Covid-19, European Stroke Journal (2023)
15. The Predictive Factors of Recurrent Deep Vein Thrombosis, ARYA Atherosclerosis (2011)
16. The Effects of Curcumin-Piperine Supplementation on Inflammatory, Oxidative Stress and Metabolic Indices in Patients With Ischemic Stroke in the Rehabilitation Phase: A Randomized Controlled Trial, Nutrition Journal (2023)
17. On-Admission Versus In-Hospital Thromboembolism Due to Covid-19 Infection. What Is the Particular Characteristic of Those With Early Thrombotic Events?, Advances in Respiratory Medicine (2021)
18. Bacterial Staphylokinase As a Promising Third-Generation Drug in the Treatment for Vascular Occlusion, Molecular Biology Reports (2020)
19. Cerebral Vein and Sinus Thrombosis in Isfahan-Iran: A Changing Profile, Canadian Journal of Neurological Sciences (2004)
20. The Frequency of Antithrombotic Therapy in Management of Non-Valvular Atrial Fibrillation in Hospitalized Patients, Journal of Isfahan Medical School (2023)
21. Genetic Thromboembolic Risk Factors Associated With Deep Vein Thrombosis in a Iranian Population, Journal of Isfahan Medical School (2011)
22. Efficacy and Safety of Apixaban for the Prevention of Thrombosis in Arteriovenous Grafts, European Journal of Translational Myology (2024)
23. Long-Term Clinical Outcomes of the Left Ventricular Thrombus in Patients With St Elevation Anterior Myocardial Infarction, ARYA Atherosclerosis (2015)
24. Assessment of Lytic Therapy Effect in Patients With Intermediate-High Risk Pulmonary Embolism for Prevention of Chronic Thromboembolic Pulmonary Hypertension: A Randomized, Double-Blind Trial, Health Science Reports (2024)
25. Low-Dose Versus Standard-Dose Alteplase for Intravenous Thrombolysis in Patients With Acute Ischemic Stroke in Iran: Results From the Safe Implementation of Treatments in Stroke Registry, Current Journal of Neurology (2021)
26. Enoxaparin Initiation After Chronic Subdural Haematoma Evacuation: A Randomized Clinical Trial on Timing and Outcomes, Surgical Practice (2023)
27. The Investigation of the Diagnostic Values of the T2wi Sequence in Cerebral Venous Sinuses Thrombosis in Comparison With 3D Mrv, Acta Medica Iranica (2020)
28. Anticoagulation Therapy in Covid-19 Patients With Chronic Kidney Disease, Journal of Research in Medical Sciences (2021)
29. Intracranial Hemorrhage in Normotensive and Hypertensive Patients Receiving Streptokinase After Decreasing Elevated Blood Pressure, Journal of Research in Medical Sciences (2005)
30. Asian Study of Cerebral Venous Thrombosis, Journal of Stroke and Cerebrovascular Diseases (2019)
31. Hormonal Contraceptives As a Risk Factor for Cerebral Venous and Sinus Thrombosis, Acta Neurologica Scandinavica (2007)
32. Evaluation of Platelet Elevation After Injection in Patients Over 40 Years of Age Admitted Hospital; a Retrospective Study, Journal of Isfahan Medical School (2017)
33. Is Thromboprophylaxis Effective in Reducing the Pulmonary Thromboembolism?, ARYA Atherosclerosis (2012)
34. Retroperitoneal Hematoma in Patients With Covid-19 Infection During Anticoagulant Therapy: A Case Series and Literature Review, Journal of International Medical Research (2022)
35. Anticoagulant and Antiplatelet Treatment Effects on the Incidence of Major Cardiovascular Events in Patients With Coronary Artery Ectasia: An Updated Systematic Review, Indian Heart Journal (2024)
36. Optimizing Acute Ischemic Stroke Outcomes: The Role of Tenecteplase Before Mechanical Thrombectomy, Clinical Therapeutics (2024)
37. Incidence of Neurological Syndromes After Thrombolytic Therapy in Elderly Patients With Acute Myocardial Infarction, Journal of Isfahan Medical School (2008)
38. Oral Contraceptive Misuse As a Risk Factor for Cerebral Venous and Sinus Thrombosis, Journal of Research in Medical Sciences (2012)
39. Antithrombotic Therapy in Adults With Ectatic Coronary Artery Disease: A Systematic Review and Network Meta-Analysis, Egyptian Heart Journal (2025)
40. The Effect of Rivaroxaban Vs Aspirin on Stroke Recurrence Among Patients With History of Cryptogenic Stroke and Left Atrial Cardiomyopathy: An Analytical Cross-Sectional Study, Neurology Asia (2022)
41. Dose Optimization Study for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke: A Study From Middle-East, Neurology Asia (2021)
42. Effective Factors in Door-To-Needle Time for Streptokinase Administration in Patients With Acute Myocardial Infarction Admitted to the Emergency Department, Trauma Monthly (2016)
43. Thrombotic Events and Anticoagulants in Beta-Thalassemia Patients With Focus on Anticoagulants for Atrial Fibrillation: A Brief Review, Current Problems in Cardiology (2022)
44. A Systematic Review on Post-Discharge Venous Thromboembolism Prophylaxis in Patients With Covid-19, Egyptian Heart Journal (2023)
45. Evaluation of the Efficacy and Safety of Rivaroxaban Compared to Warfarin in Patients With Left Ventricular Apical Thrombus: A Randomized Clinical Trial, Thrombosis Journal (2024)
46. The Effect of Clexane With Bondage and Bondage Only in Prevention of Deep Vein Thrombosis in Patients Undergoing Instrumented Spinal Surgery, Journal of Isfahan Medical School (2018)
47. A Review of Pathophysiological Mechanism, Diagnosis, and Treatment of Thrombosis Risk Associated With Covid-19 Infection, IJC Heart and Vasculature (2022)
48. Dabigatran Versus Enoxaparin in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty: A Randomized Clinical Trial, ARYA Atherosclerosis (2014)